Drug Type Small molecule drug |
Synonyms CHMFL-ABL/KIT-155 |
Target |
Action inhibitors |
Mechanism Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors), c-Kit inhibitors(Stem cell growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC33H38F3N5O3 |
InChIKeyDQHVUKLVCBJBLM-UHFFFAOYSA-N |
CAS Registry2081093-21-0 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic phase chronic myeloid leukemia | Preclinical | China | 12 Jan 2017 | |
| Gastrointestinal Stromal Tumors | Preclinical | China | 12 Jan 2017 |





